Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration | MicrobiomeTrials← Back to trialsNCT02286089
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2015-04-01Est. Completion: 2021-12-31
Enrollment target: 24 participants Locations- West Coast Retina Medical Group, San Francisco, California, United States
- Cincinnati Eye Institute, Cincinnati, Ohio, United States
- Mid Atlantic Retina, Philadelphia, Pennsylvania, United States
- Hadassah Medical Center, Jerusalem, Israel
- Rabin Medical Center, Petah Tikva, Israel
- Kaplan Medical Center, Rehovot, Israel
- Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Other microbiome trials you might be interested in
Low VisionRetinitis PigmentosaStargardt Disease 1Stargardt Disease 3Stargardt Disease 4Albinism
Purpose:
To validate a newly developed battery of performance-based tests of visual function to be presented using virt…
Belfast, United KingdomCompleted Dec 31, 2021
Geographic Atrophy Secondary to Age-Related Macular Degeneration
This study will assess the safety and efficacy of RO7965032 to address a significant unmet medical need in participants …
Walnut Creek, United States
Est. completion Aug 21, 2030
Age-Related Macular DegenerationDiabetic RetinopathyVon Hippel-Lindau SyndromeRetinal DiseaseRetinal Vein Occlusion
Background:
\- To understand diseases of the retina and the eye, information is needed about people with and without su…
Bethesda, United States